Surgical sepsis: Dysregulation of immune function and therapeutic implications

Surgeon

Volumn 1, Issue 4, 2003, Pages 187-206

  Boontham, P ^a   Chandran, P ^a   Rowlands, B ^a   Eremin, O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cytokines; Dendritic cells; MODS; Quorum sensing molecules; Sepsis; SIRS; Treatment

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; CATECHOLAMINE DERIVATIVE; CORTICOSTEROID; CYTOKINE; DOBUTAMINE; DROTRECOGIN; ENDOTOXIN; HYDROCORTISONE; INOTROPIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; NORADRENALIN; STEROID; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ANTIGEN PRESENTING CELL; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE INFECTION; REGULATORY MECHANISM; RESPIRATORY FAILURE; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING;

EID: 0042195844     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(03)80018-5     Document Type: Review

References (142)

1. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997, 10: 444-65.
2. Crowe M, Ispahani P, Humphreys H, Kelley T, Winter R. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Eur J Clin Microbiol Infect Dis 1998, 17: 377-84.
3. Angus DC, Wax RS: Epidemiology of sepsis. an update. Crit Care Med 2001, 29: S109-16.
4. Karchmer AW: Nosocomial bloodstream infections. organisms, risk factors, and implications. Clin Infect Dis 2000, 31: S139-43.
5. Lark RL, Chenoweth C, Saint S, Zemencuk JK, Lipsky BA, Plorde JJ. Four year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2000, 38: 131-40.
6. Lark RL, Saint S, Chenoweth C, Zemencuk JK, Lipsky BA, Plorde JJ. Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2001, 41: 15-22.
7. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. Jama 1995, 273: 117-23.
8. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-55.
9. Paterson RL, Webster NR. Sepsis and the systemic inflammatory response syndrome. J R Coll Surg Edinb 2000, 45:178-82.
10. Celli J, Finlay BB. Bacterial avoidance of phagocytosis. Trends Microbiol 2002, 10: 232-37.
11. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002, 20: 825-52.
12. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999, 17: 593-623.
13. Jaeschke H, Smith CW, Clemens MG, Ganey PE, Roth RA. Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 1996, 139: 213-26.
14. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002, 32: 1205-11.
15. Haeney MR. The role of the complement cascade in sepsis. J Antimicrob Chemother 1998, 41: 41-46.
16. Lebecque S. Antigen receptors and dendritic cells. Vaccine 2000, 18:1603-1605.
17. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 2000, 12: 13-19.
18. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000, 11: 219-32.
19. Akins DR, Purcell BK, Mitra MM, Norgard MV, Radolf JD. Lipid modification of the 17-kilodalton membrane immunogen of Treponema pallidum determines macrophage activation as well as amphiphilicity. Infect Immun 1993, 61: 1202-10.
20. Krutzik SR, Sieling PA, Modlin RL. The role of Toll-like receptors in host defense against microbial infection. Curr Opin Immunol 2001, 13: 104-08.
21. Muzio M, Mantovani A. Toll-like receptors. Microbes Infect 2000, 2: 251-55.
22. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000, 164: 5998-6004.
23. Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001, 11: 304-11.
24. Muzio M, Mantovani A. The Toll receptor family. Allergy 2001, 56: 103-08.
25. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999, 274: 17406-09.
26. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285: 732-36.
27. Michelsen KS, Aicher A, Mohaupt M, Hartung T, Dimmeler S, Kirschning CJ et al. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 2001, 276: 25680-86.
28. Satthaporn S, Eremin O. Dendritic cells (I): Biological functions. J R Coll Surg Edinb 2001, 46: 9-19.
29. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18: 767-811.
30. Steinman RM, Inaba K: Myeloid dendritic cells. J Leukoc Biol 1999, 66: 205-08.
31. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM: Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001, 166: 249-55.
32. Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 2001, 22: 78-83.
33. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001, 166: 5688-94.
34. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000, 12: 114-21.
35. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001, 13: 275-82.
36. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity 2001, 14:495-98.
37. Galley HF, Webster NR. The immuno-inflammatory cascade. Br J Anaesth 1996, 77: 11-16.
38. Ria F, Penna G, Adorini L. Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur J Immunol 1998, 28: 2003-16.
39. Reis e Sousa C, Sher A, Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 1999, 11: 392-99.
40. Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, Takayama T et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001, 98: 1512-23.
41. Burton G, Keele B, Estes J, Thacker T, Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 2002, 14: 275.
42. Piguet V, Blauvelt A. Essential Roles for Dendritic Cells in the Pathogenesis and Potential Treatment of HIV Disease. J Invest Dermatol 2002, 119: 365-69.
43. Wick MJ. The role of dendritic cells during Salmonella infection. Curr Opin Immunol 2002, 14: 437-43.
44. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH et al. Depletion of Dendritic Cells, But Not Macrophages, in Patients with Sepsis. J Immunol 2002, 168: 2493-500.
45. Uyemura K, Castle SC, Makinodan T. The frail elderly: role of dendritic cells in the susceptibility of infection. Mech Ageing Dev 2002, 123: 955-62.
46. Koch E, Klaas CA, Rungeler P, Castro V, Mora G, Vichnewski W, Merfort I. Inhibition of inflammatory cytokine production and lymphocyte proliferation by structurally different sesquiterpene lactones correlates with their effect on activation of NF-kappaB. Biochem Pharmacol 2001, 62: 795-801.
47. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996, 77: 110-17.
48. Adrie C, Pinsky MR. The inflammatory balance in human sepsis. Intensive Care Med 2000, 26: 364-75.
49. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994, 45: 491-503.
50. Nystrom PO. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother 1998, 41: 1-7.
51. Walley KR, Lukacs NW, Standiford TJ, Stricter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996, 64: 4733-38.
52. Steinhauser ML, Hogaboam CM, Matsukawa A, Lukacs NW, Strieter RM, Kunkel SL. Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect Immun 2000, 68: 6108-14.
53. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985, 229: 869-71.
54. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330: 662-64.
55. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988, 81: 1925-37.
56. Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993, 21: S423-35.
57. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000, 181: 176-80.
58. Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in sirs general medical patients. Cytokine 2001, 15: 232-36.
59. McAllister SK, Bland LA, Arduino MJ, Aguero SM, Wenger PN, Jarvis WR. Patient cytokine response in transfusion-associated sepsis. Infect Immun 1994, 62: 2126-28.
60. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997, 112: 321S-29S.
61. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993, 119: 771-78.
62. Borden EC, Chin P. Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994, 123: 824-29.
63. Spittler A, Razenberger M, Kupper H, Kaul M, Hackl W, Boltz-Nitulescu G et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis 2000, 31: 1338-42.
64. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996, 24: 733-42.
65. Chollet-Martin S, Montravers P, Gibert C, Elbim C, Desmonts JM, Fagon JY et al. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 1993, 61: 4553-59.
66. Hack CE, Hart M, van Schijndel RJ, Eerenberg AJ, Nuijens JH, Thijs LG et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992, 60: 2835-42.
67. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19: 683-765.
68. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174: 1209-20.
69. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993, 177: 547-50.
70. van der Poll T, Marchant A, Buurman WA, Berman L, Keogh CV, Lazarus DD et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995, 155: 5397-401.
71. Marchant A, Alegre ML, Hakim A, Pierard G, Marecaux G, Friedman G et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995, 15: 266-73.
72. van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997, 175: 118-22.
73. Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997, 12: 183-87.
74. Ertel W, Keel M, Bonaccio M, Steckholzer U, Gallati H, Kenney JS et al. Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma 1995, 39: 879-85; discussion 885-77.
75. Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC, Jr. Release of anti-inflammatory mediators after major torso trauma correlates with the development of postinjury multiple organ failure. Am J Surg 1999, 178: 564-69.
76. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998, 16: 457-99.
77. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993, 82: 2985-90.
78. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997, 112: 235-43.
79. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995, 332: 27-37.
80. Parker MM. Pathophysiology of cardiovascular dysfunction in septic shock. New Horiz 1998, 6: 130-38.
81. McDonough KH, Smith T, Patel K, Quinn M. Myocardial dysfunction in the septic rat heart: role of nitric oxide. Shock 1998, 10: 371-76.
82. Rees DD. Role of nitric oxide in the vascular dysfunction of septic shock. Biochem Soc Trans 1995, 23: 1025-29.
83. Grocott-Mason RM, Shah AM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med 1998, 24: 286-95.
84. Suffredini AF. Myocardial dysfunction in sepsis: clinical and experimental investigations. Schweiz Med Wochenschr 1998, 128: 1444-52.
85. Thijs A, Thijs LG. Pathogenesis of renal failure in sepsis. Kidney Int Suppl 1998, 66: S34-37.
86. Groeneveld AB. Pathogenesis of acute renal failure during sepsis. Nephrol Dial Transplant 1994, 9: 47-51.
87. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998, 24: 336-42.
88. Karima R, Matsumoto S, Higashi H, Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999, 5: 123-32.
89. Dhainaut JF, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001, 29: S42-47.
90. Ring A, Stremmel W. The hepatic microvascular responses to sepsis. Semin Thromb Hemost 2000, 26: 589-94.
91. Satoi S, Kamiyama Y, Kitade H, Kwon AH, Takahashi K, Wei T et al. Nitric oxide production and hepatic dysfunction in patients with post-operative sepsis. Clin Exp Pharmacol Physiol 2000, 27: 197-201.
92. Kennedy JA, Clements WD, Kirk SJ, McCaigue MD, Campbell GR, Erwin PJ et al. Characterization of the Kupffer cell response to exogenous endotoxin in a rodent model of obstructive jaundice. Br J Surg 1999, 86: 628-33.
93. Hirata K, Ikeda S, Honma T, Mitaka T, Furuhata T, Katsuramaki T et al. Sepsis and cholestasis: basic findings in the sinusoid and bile canaliculus. J Hepatobiliary Pancreat Surg 2001, 8: 20-26.
94. Nauwynck M, Huyghens L. Neurological complications in critically ill patients; septic encephalopathy, critical illness polyneuropathy. Acta Clin Belg 1998, 53: 92-97.
95. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996, 24: 1408-16.
96. Witt NJ, Zochodne DW, Bolton CF, Grand'Maison F, Wells G, Young GB et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991, 99: 176-84.
97. Rowlands BJ, Soong CV, Gardiner KR. The gastrointestinal tract as a barrier in sepsis. Br Med Bull 1999, 55: 196-211.
98. Yu P, Martin CM. Increased gut permeability and bacterial translocation in Pseudomonas pneumonia-induced sepsis. Crit Care Med 2000, 28: 2573-77.
99. Berg RD. Bacterial translocation from the gastrointestinal tract. Trends Microbiol 1995, 3: 149-54.
100. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001, 55: 165-99.
101. Withers H, Swift S, Williams P. Quorum sensing as an integral component of gene regulatory networks in Gram-negative bacteria. Curr Opin Microbiol 2001, 4: 186-93.
102. Winzer K, Hardie KR, Williams P. Bacterial cell-to-cell communication: sorry, can't talk now - gone to lunch! Curr Opin Microbiol 2002, 5: 216-22.
103. Whitehead NA, Barnard AM, Slater H, Simpson NJ, Salmond GP. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol Rev 2001, 25: 365-404.
104. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002, 148: 87-102.
105. Watnick P, Kolter R. Biofilm, city of microbes. J Bacteriol 2000, 182: 2675-79.
106. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001, 9: 34-39.
107. Williams P, Camara M, Hardman A, Swift S, Milton D, Hope VJ et al. Quorum sensing and the population-dependent control of virulence. Philos Trans R Soc Lond B Biol Sci 2000, 355: 667-80.
108. Iwasaki A, Kelsall BL. Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Am J Physiol 1999, 276: G1074-78.
109. Bilsborough J, Viney JL. Getting to the guts of immune regulation. Immunology 2002, 106: 139-43.
110. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998, 66: 36-42.
111. Smith RS, Harris SG, Phipps R, Iglewski B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J Bacteriol 2002, 184: 1132-39.
112. Chhabra SR, Harty C, Hooi DS, Daykin M, Williams P, Telford G et al. Synthetic analogues of the bacterial signal (quorum sensing) molecule N-(3-oxododecanoyl)-L-homoserine lactone as immune modulators. J Med Chem 2003, 46: 97-104.
113. Vincent JL, Roman A, Kahn RJ. Dobutamine administration in septic shock: addition to a standard protocol. Crit Care Med 1990, 18: 689-93.
114. De Backer D, Zhang H, Manikis P, Vincent JL. Regional effects of dobutamine in endotoxic shock. J Surg Res 1996, 65: 93-100.
115. Venet C, Zeni F, Viallon A, Ross A, Pain P, Gery P et al. Endotoxaemia in patients with severe sepsis or septic shock. Intensive Care Med 2000, 26: 538-44.
116. Marshall JC, Walker PM, Foster DM, Harris D, Ribeiro M, Paice J et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002, 6: 342-48.
117. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001, 29: S90-94.
118. Giudici D, Baudo F, Palareti G, Ravizza A, Ridolfi L, A DA. Antithrombin replacement in patients with sepsis and septic shock. Haematologica 1999, 84: 452-60.
119. Ziegler EJ, Fisher CJ, Jr., Sprung CL, Straube RC, Sadoff JC, Foulke GE et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991, 324: 429-36.
120. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. Jama 1991, 266: 1097-102.
121. Di Padova FE, Brade H, Barclay GR, Poxton IR, Liehl E, Schuetze E et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 1993, 61: 3863-72.
122. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996, 24: 1431-40.
123. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998, 351: 929-33.
124. Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001, 27: 1169-78.
125. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H. Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 2001, 182: 491-97.
126. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001, 29: S121-25.
127. Healy DP. New and emerging therapies for sepsis. Ann Pharmacother 2002, 36:648-654.
128. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000, 28: S31-33.
129. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama 2001, 286: 1869-78.
130. Fisher CJ, Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Jama 1994, 271: 1836-43.
131. Gershenwald JE, Fong YM, Fahey TJ, 3rd, Calvano SE, Chizzonite R, Kilian PL et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990, 87: 4966-70.
132. Knaus WA, Harrell FE, Fisher CJ, Jr., Wagner DP, Opal SM, Sadoff JC et al. The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. Jama 1993, 270: 1233-41.
133. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997, 25: 1115-24.
134. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992, 89: 4845-49.
135. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991, 21: 2883-86.
136. Fisher CJ, Jr., Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334: 1697-702.
137. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. Jama 1997, 277: 1531-38.
138. Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002, 6: 251-59.
139. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama 2002, 288: 862-71.
140. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001, 12: S70-74.
141. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27: 723-32.
142. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26: 645-50.